S

Shanghai Henlius Biotech
2696

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
HK$21.17B
EV
HK$24.19B
Shares Outstanding
543.49M
Beta
0.83

Wall Street View

Analyst Rating
HOLD
Analyst Target Price
HK$32.68
P/E 2025E
-
P/Revenue 2025E
3.46x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Shanghai Henlius Biotech, Inc.

gainify

S

Shanghai Henlius Biotech, Inc.

2696

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leuke...

Sector

Healthcare

Industry

Biotechnology

CEO

Zhu, Jun

Employees

3,515

IPO Date

2019-09-25

Headquarters

Building B8, 11th Floor, 188 Yizhou Road, Xuhui District, Shanghai 200233, China

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved